211 related articles for article (PubMed ID: 27058226)
1. Carfilzomib alters the HLA-presented peptidome of myeloma cells and impairs presentation of peptides with aromatic C-termini.
Kowalewski DJ; Walz S; Backert L; Schuster H; Kohlbacher O; Weisel K; Rittig SM; Kanz L; Salih HR; Rammensee HG; Stevanović S; Stickel JS
Blood Cancer J; 2016 Apr; 6(4):e411. PubMed ID: 27058226
[TBL] [Abstract][Full Text] [Related]
2. Features of TAP-independent MHC class I ligands revealed by quantitative mass spectrometry.
Weinzierl AO; Rudolf D; Hillen N; Tenzer S; van Endert P; Schild H; Rammensee HG; Stevanović S
Eur J Immunol; 2008 Jun; 38(6):1503-10. PubMed ID: 18446792
[TBL] [Abstract][Full Text] [Related]
3. A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and "pan-leukemia" antigens.
Backert L; Kowalewski DJ; Walz S; Schuster H; Berlin C; Neidert MC; Schemionek M; Brümmendorf TH; Vucinic V; Niederwieser D; Kanz L; Salih HR; Kohlbacher O; Weisel K; Rammensee HG; Stevanovic S; Walz JS
Oncotarget; 2017 Jul; 8(27):43915-43924. PubMed ID: 28159928
[TBL] [Abstract][Full Text] [Related]
4. Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma.
Hundemer M; Schmidt S; Condomines M; Lupu A; Hose D; Moos M; Cremer F; Kleist C; Terness P; Belle S; Ho AD; Goldschmidt H; Klein B; Christensen O
Exp Hematol; 2006 Apr; 34(4):486-96. PubMed ID: 16569595
[TBL] [Abstract][Full Text] [Related]
5. Long-term immunity against actual poxviral HLA ligands as identified by differential stable isotope labeling.
Meyer VS; Kastenmuller W; Gasteiger G; Franz-Wachtel M; Lamkemeyer T; Rammensee HG; Stevanovic S; Sigurdardottir D; Drexler I
J Immunol; 2008 Nov; 181(9):6371-83. PubMed ID: 18941228
[TBL] [Abstract][Full Text] [Related]
6. Efficiency and mechanism of antigen-specific CD8+ T-cell activation using synthetic long peptides.
Zandvliet ML; Kester MG; van Liempt E; de Ru AH; van Veelen PA; Griffioen M; Guchelaar HJ; Falkenburg JH; Meij P
J Immunother; 2012; 35(2):142-53. PubMed ID: 22306902
[TBL] [Abstract][Full Text] [Related]
7. The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy.
Walz S; Stickel JS; Kowalewski DJ; Schuster H; Weisel K; Backert L; Kahn S; Nelde A; Stroh T; Handel M; Kohlbacher O; Kanz L; Salih HR; Rammensee HG; Stevanović S
Blood; 2015 Sep; 126(10):1203-13. PubMed ID: 26138685
[TBL] [Abstract][Full Text] [Related]
8. Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation.
Bassani-Sternberg M; Pletscher-Frankild S; Jensen LJ; Mann M
Mol Cell Proteomics; 2015 Mar; 14(3):658-73. PubMed ID: 25576301
[TBL] [Abstract][Full Text] [Related]
9. Carfilzomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of HLA class I.
Yang G; Gao M; Zhang Y; Kong Y; Gao L; Tao Y; Han Y; Wu H; Meng X; Xu H; Zhan F; Wu X; Shi J
Oncotarget; 2015 Sep; 6(29):26982-94. PubMed ID: 26323098
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic targeting of naturally presented myeloperoxidase-derived HLA peptide ligands on myeloid leukemia cells by TCR-transgenic T cells.
Klar R; Schober S; Rami M; Mall S; Merl J; Hauck SM; Ueffing M; Admon A; Slotta-Huspenina J; Schwaiger M; Stevanović S; Oostendorp RA; Busch DH; Peschel C; Krackhardt AM
Leukemia; 2014 Dec; 28(12):2355-66. PubMed ID: 24736212
[TBL] [Abstract][Full Text] [Related]
11. Proteasome-inhibited dendritic cells demonstrate improved presentation of exogenous synthetic and natural HLA-class I peptide epitopes.
Chromik J; Schnürer E; Georg Meyer R; Wehler T; Tüting T; Wölfel T; Huber C; Herr W
J Immunol Methods; 2006 Jan; 308(1-2):77-89. PubMed ID: 16336973
[TBL] [Abstract][Full Text] [Related]
12. Biogenesis of HLA Ligand Presentation in Immune Cells Upon Activation Reveals Changes in Peptide Length Preference.
Marino F; Semilietof A; Michaux J; Pak HS; Coukos G; Müller M; Bassani-Sternberg M
Front Immunol; 2020; 11():1981. PubMed ID: 32983136
[TBL] [Abstract][Full Text] [Related]
13. Mass spectrometric analysis of the HLA class I peptidome of melanoma cell lines as a promising tool for the identification of putative tumor-associated HLA epitopes.
Gloger A; Ritz D; Fugmann T; Neri D
Cancer Immunol Immunother; 2016 Nov; 65(11):1377-1393. PubMed ID: 27600516
[TBL] [Abstract][Full Text] [Related]
14. Tripeptidyl peptidase II is dispensable for the generation of both proteasome-dependent and proteasome-independent ligands of HLA-B27 and other class I molecules.
Marcilla M; Villasevil EM; de Castro JA
Eur J Immunol; 2008 Mar; 38(3):631-9. PubMed ID: 18286573
[TBL] [Abstract][Full Text] [Related]
15. Invariant chain as a vehicle to load antigenic peptides on human MHC class I for cytotoxic T-cell activation.
Wälchli S; Kumari S; Fallang LE; Sand KM; Yang W; Landsverk OJ; Bakke O; Olweus J; Gregers TF
Eur J Immunol; 2014 Mar; 44(3):774-84. PubMed ID: 24293164
[TBL] [Abstract][Full Text] [Related]
16. Proteasome inhibitors reconstitute the presentation of cytotoxic T-cell epitopes in Epstein-Barr virus-associated tumors.
Gavioli R; Vertuani S; Masucci MG
Int J Cancer; 2002 Oct; 101(6):532-8. PubMed ID: 12237893
[TBL] [Abstract][Full Text] [Related]
17. A large fraction of HLA class I ligands are proteasome-generated spliced peptides.
Liepe J; Marino F; Sidney J; Jeko A; Bunting DE; Sette A; Kloetzel PM; Stumpf MP; Heck AJ; Mishto M
Science; 2016 Oct; 354(6310):354-358. PubMed ID: 27846572
[TBL] [Abstract][Full Text] [Related]
18. Cell Surface MHC Class I Expression Is Limited by the Availability of Peptide-Receptive "Empty" Molecules Rather than by the Supply of Peptide Ligands.
Komov L; Kadosh DM; Barnea E; Milner E; Hendler A; Admon A
Proteomics; 2018 Jun; 18(12):e1700248. PubMed ID: 29707912
[TBL] [Abstract][Full Text] [Related]
19. Interaction of HLA-E with peptides and the peptide transporter in vitro: implications for its function in antigen presentation.
Ulbrecht M; Modrow S; Srivastava R; Peterson PA; Weiss EH
J Immunol; 1998 May; 160(9):4375-85. PubMed ID: 9574542
[TBL] [Abstract][Full Text] [Related]
20. Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24.
Christensen O; Lupu A; Schmidt S; Condomines M; Belle S; Maier A; Hose D; Neuber B; Moos M; Kleist C; Terness P; Ho AD; Goldschmidt H; Klein B; Hundemer M
J Immunother; 2009; 32(6):613-21. PubMed ID: 19483648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
